According to a report from Ernst & Young, the Nordic Life Sciences Sector raised €11,300 million ($14,607 million) in capital in 2013. Sales of biotechnology and medical technology companies accounted for €3,980 million and €7,300 million in revenues, respectively. Within the life sciences, the pharmaceutical industry was dominant, followed by medtech and biotech. Among European […]
The Chinese Academy of Sciences (CAS), which has a budget of approximately $6.8 billion and encompasses 104 research institutes, is undergoing a restructuring. About half of its funds are provided by the government and are used for overhead costs and a portion of salaries, with the remaining funding from competitive government grants. The restructuring is […]
Some Indian drug companies are moving R&D and clinical trials abroad as they seek to expand the types of products they sell and bring drugs to market faster. Piramal Enterprises, Sun Pharmaceutical Industries and Lupin have announced such plans. Indian firms are pursuing sales of higher-margin products, such as drugs for niche markets, products that […]
A survey of 48 finance directors (FDs) of higher-education institutions (HEI), representing 37% of the sector, has revealed that 36% of them feel less positive about the financial prospects of their institutions compared with the previous year, whereas 23% are more optimistic. Asked to describe their “general level of external or financial economic uncertainty,” 89% […]
According to newly required annual department reports of China’s central government agencies, 2011 R&D spending was CNY 73.7 billion ($11.4 billion), 9% of gross domestic expenditure on R&D (GERD) or 39% of government contributions to GERD. Agencies also receive research funds from sources such as businesses and local governments. The Ministry of Science and Technology […]
This fall’s edition of IBO’s biannual article highlighting selected new laboratory construction and openings focuses on academic and industrial investments. The table on page 4 lists new projects in the automobile industry and at medical schools. New labs in China, the UK, Europe and the US are also highlighted. China Several companies have recently announced […]
The food-processing sector constitutes up to 10% of the GDP within India’s Agriculture and Manufacturing sector. Agriculture employs about 60% of the population and contributes 14% to the GDP. In fiscal 2012, India produced 127.3 million t of milk, representing 17% of the global market. The country produced 7.0 million t of pulses, 155.7 million […]
R&D spending by Germany’s chemical industry was a record high of €10.5 billion ($14.1 billion) in 2013, up 8.2%. The number of personnel researching new products or processes grew by just under 5% to 44,500, while the growth of staff in the overall sector increased by 1.3%. The chemical sector had the third-largest research budget […]
An August report by Cochilco, Chile’s copper commission, states that the country’s mining investment is expected to be $105 billion between 2014 and 2023, a decrease of 7.5% from last year’s estimate. Projects in the copper industry will receive $81 billion, while $23 billion will be for projects in gold, silver, iron ore and other […]
R&D spending by 264 Japanese companies will increase 4% this fiscal year to JPY 11.6 trillion ($112 billion), compared to a 5.4% increase in fiscal 2014, according to a survey by Nikkei. About 20% of those firms will be building or expanding their R&D facilities overseas. The companies investing the most in R&D are Toyota […]
Pay Invoice
Latest Blogs
-
Lab Instrument Sales in China Collapse
March 29, 2024 1:15 pm
-
Pittcon 2024 Comes to San Diego
February 14, 2024 1:10 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
